Revenue: As of FY2025 Q1, the actual value is USD 897.84 M, missing the estimate of USD 983.75 M.EPS: As of FY2025 Q1, the actual value is USD -1.52, missing the estimate of USD 1.4381.EBIT: As of FY2025 Q1, the actual value is USD -109.81 M.<h3>Segment Revenue</h3><ul><li>Neuroscience: Xywav sales increased by 9% to $344.8 million, driven by increased sales volumes and higher selling prices, offset by higher gross to net deductions. Xyrem sales decreased by 42% to $37.2 million due to decreased sales volumes and higher gross to net deductions. Epidiolex/Epidyolex sales increased by 10% to $217.7 million, driven by lower gross to net deductions, higher average selling prices, and increased sales volumes.</li><li>Oncology: Rylaze/Enrylaze sales decreased by 8% to $94.2 million due to decreased sales volumes. Zepzelca sales decreased by 16% to $63.0 million due to decreased sales volumes. Defitelio/defibrotide sales decreased by 15% to $40.7 million due to decreased sales volumes and negative foreign exchange rates. Vyxeos sales decreased by 8% to $29.5 million due to decreased sales volumes and negative foreign exchange rates.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: The company reported a net loss of $92.5 million for the three months ended March 31, 2025, compared to a net loss of $14.6 million for the same period in 2024.</li><li>Gross Margin: Gross margin as a percentage of net product sales was 87.5% for the three months ended March 31, 2025, compared to 88.7% for the same period in 2024.</li><li>Selling, General and Administrative Expenses: Increased by 46% to $514.0 million, primarily due to certain Xyrem antitrust litigation settlements of $172.0 million.</li><li>Research and Development Expenses: Decreased by 19% to $180.7 million, primarily due to lower costs related to zanidatamab and discontinued programs.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash provided by operating activities increased to $429.8 million for the three months ended March 31, 2025, compared to $267.2 million for the same period in 2024.</li><li>Investing Activities: Net cash used in investing activities was $168.9 million, primarily due to acquisition of investments and milestone payments.</li><li>Financing Activities: Net cash used in financing activities was $813.5 million, primarily due to the voluntary repayment on the Tranche B-2 Dollar Term Loan.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue focusing on research and development activities within neuroscience and oncology therapeutic areas, with a strategy to drive diversified revenue growth and address unmet medical needs.</li><li>Non-Core Business: The company completed the acquisition of Chimerix, which is expected to enhance its pipeline with dordaviprone, a novel treatment in development for H3 K27M-mutant diffuse glioma.</li><li>Priority: The company aims to deliver sustainable growth through strong commercial execution, expanding its pipeline, and investing in an efficient operating model.</li></ul>

Jazz Pharma | 10-Q: FY2025 Q1 Revenue Misses Estimate at USD 897.84 M